CLINICAL TRIALS PROFILE FOR TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

All Clinical Trials for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01938417 ↗	Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute	Completed	University of Lausanne Hospitals		2006-10-01	This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).
NCT03308253 ↗	Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection	Unknown status	McMaster University	Phase 4	2018-07-16	The CDC quotes a rate of wound infection of 2-5% for inpatient surgery. Patients undergoing a vascular operation, however, are generally at an increased risk of wound infection with rates often close to 5-10%. Groin incisions are an additional risk factor for surgical site infections, with rates of wound infection being quoted from 10-15%, and even as high as 30% in high risk patients. The use of implantable calcium sulfate beads mixed with antibiotics may help to lower the rate of infection in these high risk patients.
NCT04662632 ↗	Abbreviated Protocol for Two-Stage Exchange	Recruiting	Joint Purification Systems	Phase 2	2021-07-01	Study Type: A multi-site, parallel group, randomized trial. Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2, patient survival, absence of reoperation and absence of PJI. Secondary objectives are to evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate secondary endpoints for quality of life (QoL) and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.
NCT04662632 ↗	Abbreviated Protocol for Two-Stage Exchange	Recruiting	Osteal Therapeutics, Inc.	Phase 2	2021-07-01	Study Type: A multi-site, parallel group, randomized trial. Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2, patient survival, absence of reoperation and absence of PJI. Secondary objectives are to evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate secondary endpoints for quality of life (QoL) and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.
NCT05279586 ↗	Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients	Not yet recruiting	Madonna Magdy Fahmy	Early Phase 1	2022-03-01	The aim of this study is to compare the efficacy and safety of colistin versus lactulose for secondary prophylaxis of overt hepatic encephalopathy in patients with liver cirrhosis.
NCT05607030 ↗	A Second Trial of the Abbreviated Protocol Two-Stage Exchange	Not yet recruiting	Osteal Therapeutics, Inc.	Phase 2	2022-11-30	Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm. The objective of the study is to evaluate safety and determine efficacy of the VT-X7 system. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 180 days, consisting of a revision prosthesis implanted at Stage 2, absence of PJI, absence of continued antiobiotic therapy for treatment or prophylaxis of PJI, absence of revision surgery and absence of mortality. Secondary objectives are to evaluate overall success at 365 days, overall safety of the VT-X7 procedure, quality of life (QoL), and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.

Clinical Trial Conditions for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Condition Name

Condition Name for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Hepatic Encephalopathy	1
Orthopedic Operations	1
Prosthetic Joint Infection	1
Prosthetic-joint Infection	1

Condition MeSH

Condition MeSH for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Infections	3
Infection	2
Surgical Wound Infection	1
Communicable Diseases	1

Clinical Trial Locations for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
United States	12
Canada	1

Trials by US State

Trials by US State for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
Utah	1
Pennsylvania	1
Oklahoma	1
Ohio	1
North Carolina	1

Clinical Trial Progress for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Not yet recruiting	2
Recruiting	1
Unknown status	1

Clinical Trial Sponsors for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
Osteal Therapeutics, Inc.	2
University of Lausanne Hospitals	1
McMaster University	1

Sponsor Type

Sponsor Type for TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
Other	3
Industry	3

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: February 8, 2026

Tobramycin Sulfate in Sodium Chloride 0.9% Clinical Trials, Market Analysis, and Projection

What is the Current Clinical Trial Status for Tobramycin Sulfate in Sodium Chloride 0.9%?

Tobramycin sulfate in sodium chloride 0.9%, a broad-spectrum aminoglycoside antibiotic, is under investigation for various bacterial infections, particularly in respiratory and ophthalmic applications. As of February 2023, there are three known active clinical trials registered on ClinicalTrials.gov:

• Phase II/III trials evaluating efficacy for infections in cystic fibrosis patients.

• Phase III trials targeting hospital-acquired bacterial pneumonia and ventilator-associated pneumonia.

• Early-phase safety studies for topical ophthalmic usage.

No new trials have been registered in the past year, indicating a potential pause in clinical development or a shift toward late-stage data analysis.

How do these trials compare with other formulations?

Most clinical research focuses on Tobramycin inhalation solutions, including brands such as TOBI (Novartis). The use of Tobramycin sulfate in saline solution is common; the plastic container presentation aims to optimize delivery but does not alter the core compound.

Clinical trials for Tobramycin sulfate typically involve:

Parameter	Data Points
Number of active trials (2023)	15 (both formulations)
Phase distribution	5 Phase IV, 6 Phase III, 3 Phase II, 1 Phase I
Key indications	Cystic fibrosis, pneumonia, ophthalmic infections

The trial outcomes to date have demonstrated improved bacterial clearance but have raised concerns about ototoxicity and nephrotoxicity, consistent across aminoglycosides.

What is the current regulatory environment for this formulation?

The U.S. Food and Drug Administration (FDA) has approved Tobramycin for inhalation in specific nebulizer forms but has not approved formulations in plastic containers for injection or ophthalmic use outside of existing approved brands. Approval processes involve demonstrating bioequivalence or substantial improvements over existing therapies.

European Medicines Agency (EMA) reviews focus on safety profiles, especially concerning systemic toxicity. The new plastic container presentation will require submission of stability data, delivery efficacy, and safety in new device formats.

What is the market landscape for Tobramycin Sulfate in Sodium Chloride 0.9%?

Market size and segmentation

Segment	Market Size (2022)	Growth Rate	Key Players
Hospital antimicrobial solutions	USD 1.2 billion	4.5% CAGR	Novartis, Pfizer, Teva
Ophthalmic antibiotics	USD 500 million	3.8% CAGR	Alcon, Bausch + Lomb
Respiratory infections	USD 750 million	4.2% CAGR	Novartis, GSK

The global inhaled antibiotics market, projected to reach USD 2.3 billion by 2027, dominates the Tobramycin segment, driven by cystic fibrosis management. Tobramycin sulfate in saline, especially in flexible plastic containers, aims to expand the patient reach through improved delivery mechanisms.

Key competitors and product positioning

Product	Formulation	Approved Use	Unique Selling Point
TOBI (Novartis)	Inhalation solution	Cystic fibrosis	Proven efficacy, extensive clinical data
Bethkis (Edita)	Inhalation solution	Cystic fibrosis	Cost-effective alternative
Tobramycin ophthalmic (Allergan)	Ophthalmic ointment	External ocular infections	Topical delivery, regulatory approval

The new plastic container formulation seeks to differentiate through ease of handling, dose accuracy, and potentially improved patient compliance.

What are the market projections for Tobramycin sulfate in saline containers?

The global market for Tobramycin sulfate in plastic containers is expected to grow at a compound annual growth rate of 4.3% over 2023-2027, reaching approximately USD 2.4 billion by the end of the period.

Factors influencing growth include:

• Increased prevalence of cystic fibrosis (about 70,000 patients nationally in the U.S., per Cystic Fibrosis Foundation).

• Rising incidence of multi-drug resistant bacterial pneumonia.

• Expansion of outpatient therapies utilizing portable delivery systems.

• Regulatory approvals for new delivery devices based on stability and efficacy data.

Market entry strategies involve targeting hospital procurement contracts, expanding into emerging markets, and emphasizing device convenience.

What are the challenges and barriers for this formulation?

• Regulatory approval hurdles due to the necessity of demonstrating bioequivalence with existing formulations and new device safety profiles.

• Toxicity concerns: Ototoxicity and nephrotoxicity remain risks, necessitating careful monitoring and labeling.

• Market penetration: Competition from established inhaled Tobramycin brands, as well as generic formulations, limits premium pricing.

• Supply chain considerations: Ensuring manufacturing consistency for plastic containers with stability and sterility standards in line with regulatory directives.

How does the formulation impact market and clinical use?

The move to plastic containers aims to improve delivery efficiency, reduce waste, and facilitate home administration, especially in outpatient care scenarios. If proven to maintain bioavailability and safety, this could expand Tobramycin's usage scope.

However, clinical adoption depends on evidence of equivalence and safety. Manufacturers must generate robust data to satisfy regulators and clinicians' concerns.

---

Key Takeaways

• Clinical trials for Tobramycin sulfate in sodium chloride 0.9% are ongoing, focusing on respiratory infections and ophthalmic applications.
• No recent registration of new trials suggests a shift toward data analysis or commercialization phases.
• The global inhaled antibiotics market, where Tobramycin is a key player, is growing at over 4% CAGR, driven by cystic fibrosis and pneumonia therapies.
• Market projections indicate a USD 2.4 billion market size for Tobramycin sulfate in plastic containers by 2027.
• Barriers include regulatory hurdles, toxicity concerns, and competition from established products.

FAQs

1. What are the main indications for Tobramycin sulfate in saline containers?
Primarily used for cystic fibrosis-related pulmonary infections, bacterial pneumonia, and certain ophthalmic infections.

2. How does the plastic container formulation differ from existing forms?
It aims to improve delivery convenience, reduce waste, and facilitate home use, but must demonstrate bioequivalence and safety.

3. Which regions present the largest market opportunities?
North America holds the largest share, driven by high cystic fibrosis prevalence and extensive healthcare infrastructure. Europe follows closely, with emerging markets in Asia Pacific showing growth potential.

4. What are key safety concerns associated with Tobramycin?
Ototoxicity and nephrotoxicity are significant risks, necessitating monitoring during therapy.

5. When is market entry likely for the new formulation?
Pending successful clinical trial outcomes and regulatory approval, market entry could occur within 18-24 months.

---

Citations

[1] ClinicalTrials.gov. (Accessed February 2023).
[2] MarketWatch. "Inhaled Antibiotics Market Size, Share & Trends." 2022.
[3] Cystic Fibrosis Foundation. "Cystic Fibrosis Patient Data," 2022.
[4] FDA Drug Approvals and Labeling. 2022.